Podium to Practice: ESMO® 2025 – GI: LEAP-014
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA79 – Lenvatinib plus Pembrolizumab and Chemotherapy vs Pembrolizumab and Chemotherapy in Untreated Metastatic Esophageal Squamous Cell Carcinoma: The Randomized Phase 3 LEAP-014 Study
This program has been made possible through unrestricted support from Amgen.
Studies/trials discussed:
LBA79 – Lenvatinib plus Pembrolizumab and Chemotherapy vs Pembrolizumab and Chemotherapy in Untreated Metastatic Esophageal Squamous Cell Carcinoma: The Randomized Phase 3 LEAP-014 Study
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.